Shanghai Fosun Pharmaceutical (HKG:2196, SHA:600196) obtained breakthrough therapy designation for its FCN-159 anti-cancer tablets, according to a Monday filing with the Hong Kong bourse.
The drug registration application is for the treatment of three indications of histiocytic neoplasms or abnormal white blood cell proliferation in adults with inoperable or post-operative residual/recurrent NF1-associated PNs and children with Langerhans cell histiocytosis, which causes lesions, the filing said.
Subsidiary Shanghai Fosun Pharmaceutical Industrial Development developed the drug.
Shares rose 2% in Shanghai during Tuesday's afternoon trading.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.